Lawrence Eichenfield, MD; and Rocco Serrao, MD, react to roflumilast approval for pediatric atopic dermatitis

A newly approved nonsteroidal topical agent offers pediatricians and caregivers an additional treatment option for young children with atopic dermatitis (AD). Lawrence Eichenfield, MD; and Rocco Serrao, MD, discussed the expanded indication of roflumilast 0.05% cream (Zoryve; Arcutis Biotherapeutics), a phosphodiesterase 4 inhibitor, for children aged 2 to 5 years with mild to moderate AD.